Navigation Links
AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
Date:1/9/2013

Alachua, FL (PRWEB) January 09, 2013

AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today that AxoGen products will be featured in an educational forum at the combined 2013 Annual Meetings of The American Association for Hand Surgery (AAHS), The American Society for Peripheral Nerve (ASPN), and The American Society for Reconstructive Microsurgery (ASRM) in Naples, Florida, January 9-15.

“Surgeons are rethinking their approaches for peripheral nerve repair,” said Karen Zaderej, CEO for AxoGen. “AxoGen’s educational symposium and panel discussion will provide them with valuable insights on regenerative clinical solutions for their patients with peripheral nerve injuries.”

The Symposium and Panel Discussion entitled, “My New Treatment Algorithm: Peripheral Nerve Injuries”, will feature Ivica Ducic, MD, PhD as Moderator, and panelists Bauback Safa, MD, MBA, FACS, Patrick Basile, MD, and Erick DeVinney, BS, Director of Clinical and Translational Sciences for AxoGen. The event is scheduled for Thursday, January 10, 2013 from 1:00-2:00 pm and is open to all registered attendees of the AAHS meeting.

In addition, AxoGen will be exhibiting its technologies and products at Booth 42 at the AAHS, ASPN and ASRM meetings.

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at http://www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10303387.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Ecig Advanced Sponsors Lexington's First Annual Vaping Event
2. AAO-sponsored research shows cataract surgery can reduce hip fracture risk
3. MotoSport.com Sponsors the 2013 Spinechillers Racing Arenacross Team
4. Marketing Xocolate International Corporation Sponsors The Xo-Love Project, An International Humanitarian Effort, to Increase Charitable Donations And Community Outreach
5. Agenda set for upcoming CRF-sponsored conference on stem cell therapy for heart disease
6. PhUSE Co-sponsors the Annual FDA/PhUSE Computational Science Symposium, in Silver Spring Maryland, USA, March 18th-19th 2013
7. Psychoeducational intervention changes patient attitudes on clinical trials participation
8. The Alzheimer’s Caregiver™ Offers a New Educational Concept of Care That Bridges the Gap between Research and Caregiving
9. LA BioMed offers unique educational and research opportunity to local high school seniors
10. Study finds asthma is not linked to lower educational attainment
11. Rectal microbicide research takes giant leap forward with groundbreaking educational video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: